NewmanMYeildingIIIMD

Hematology/Oncology

Physician

Are you Dr. Yeilding?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. Newman Yeilding III, MD is a board certified internist in Ardmore, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1991 - 1995
University of Pennsylvania Health SystemResidency, Internal Medicine, 1985 - 1988
University of Alabama School of MedicineClass of 1985

PubMed

20 citations
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives - an update: Ustekinumab development as psoriasis treatment
Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick
Annals of the New York Academy of Sciences. 2012-08-01
4 citations
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick
Annals of the New York Academy of Sciences. 2011-03-01
183 citations
Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy
Michael S. Gee, William N. Procopio, Sosina Makonnen, Michael Feldman, Newman M. Yeilding
The American Journal of Pathology. 2003-01-01

‘Patient-Controlled’ Injector Approved for TremfyaMarch 8th, 2019
Janssen Gets FDA Approval for Tremfya One-Press Patient-Controlled InjectorFebruary 28th, 2019
Janssen Submits Application Seeking FDA Approval of Stelara® (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque PsoriasisDecember 20th, 2018
Join now to see all